ストックスクリーナーアプリを入手
222.82
1.35%
-3.06
アフターアワーズ：
223.20
0.38
+0.17%
前日終値:
$225.88
開ける：
$225.5
24時間の取引高:
1.75M
Relative Volume:
1.62
時価総額：
$32.92B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
23.91
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
-1.56%
1か月 パフォーマンス:
+3.14%
6か月 パフォーマンス:
+21.24%
1年 パフォーマンス:
+44.48%
1日の値動き範囲:
$222.50
$228.31
1週間の範囲:
$222.50
$230.49
52週間の値動き範囲:
$138.00
$230.49
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
222.82 | 33.63B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,149.85 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
258.66 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.93 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.81 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.05 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
How At Home Alzheimer’s Treatment Could Impact Biogen (BIIB) Investors - Simply Wall Street
How Biogen Inc. (BIIB) Affects Rotational Strategy Timing - Stock Traders Daily
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs? - Zacks Investment Research
Biogen stock closes 0.55 percent higher as Q2 growth holds - AD HOC NEWS
Biogen (BIIB) Could Be 4% Undervalued After Strong Earnings And Product News - simplywall.st
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack - Yahoo Finance
Biogen stock slips before the bell after September 24 close - AD HOC NEWS
Biogen stock trades near its 52-week high on growth bets - AD HOC NEWS
Biogen stock adds 3.40 percent ahead of the open - AD HOC NEWS
Biogen Inc. (BIIB) Options ChainYahoo Finance - Yahoo! Finance Canada
Biogen Inc. stock reaches a new 52-week high - AD HOC NEWS
Biogen stock heads into the open after a 2.7 percent gain - AD HOC NEWS
Biogen stock hits 52-week high at 225.88 USD By Investing.com - Investing.com Australia
Biogen stock hits 52-week high at 225.88 USD - Investing.com
Biogen stock slips after a lower close and analyst notes - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent decline - AD HOC NEWS
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Learn Why The Bull Case For Biogen Stock Could Change Following At Home LEQEMBI Approval - simplywall.st
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day - Zacks Investment Research
Biogen Inc. stock holds near top of 52-week range after EMPAVELI data update - AD HOC NEWS
Biogen stock heads into the open after a 1.6 percent slide - ad-hoc-news.de
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size, Share & Growth Report, 2035 - SNS Insider
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Biogen Inc. stock reacts to Leqembi Pen approval and fresh guidance - AD HOC NEWS
Biogen acquires RayThera Inc. (August 2026) - app.dealroom.co
Biogen Inc. stock gains regulatory boost from Japan approval for Leqembi Pen - AD HOC NEWS
Biogen Inc. stock gains after new EMPAVELI kidney data publication - AD HOC NEWS
Biogen Inc. stock trades near 52-week high as analysts keep a Moderate Buy stance - AD HOC NEWS
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN - Biogen
Biogen: Growth Is Back, But It Came At A Price (NASDAQ:BIIB) - Seeking Alpha
Biogen Announces Published VALIANT Data Showing EMPAVELI Reduced Proteinuria in Adolescents with C3G and Primary IC-MPGN - Quiver Quantitative
Is Biogen Stock Outperforming the S&P 500? - finance.yahoo.com
Eisai and Biogen Announce Japan Approval of LEQEMBI Pen, a Once-Weekly Subcutaneous Alzheimer’s Treatment - Quiver Quantitative
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease - Yahoo Finance
Biogen (BIIB) Wins China Approval For At Home Weekly Alzheimer’s Treatment - simplywall.st
Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 - Biogen
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside? - Yahoo Finance
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience - Yahoo Finance
Biogen Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. (BIIB) Stock Analysis: Exploring a 9.23% Potential Upside with Strategic Collaborations - DirectorsTalk Interviews
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - TradingView
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
Biogen Inc (BIIB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Minor Lloyd | Director |
Aug 04 '26 |
Sale |
200.96 |
593 |
119,169 |
2,689 |
1.40%
大文字化:
|
ボリューム (24 時間):